Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

(2020) Sander Lefere et al.   JOURNAL OF HEPATOLOGY

Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease

(2019) Mingzhu Ni et al.   BIOMEDICINE & PHARMACOTHERAPY

Elevated oxysterol levels in human and mouse livers reflect non-alcoholic steatohepatitis

(2019) Tina Raselli et al.   JOURNAL OF LIPID RESEARCH

Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells

(2019) Kaori Endo-Umeda et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Role of Oleic Acid in the Gut-Liver Axis: From Diet to the Regulation of Its Synthesis via Stearoyl-CoA Desaturase 1 (SCD1)

(2019) Elena Piccinin et al.   Nutrients

The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View

(2018) Christina C. Lindenmeyer et al.   Clinics in Liver Disease

Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism

(2018) Preeti Pathak et al.   HEPATOLOGY

Insights into the Role of PPARβ/δ in NAFLD

(2018) Jiapeng Chen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation

(2018) Zhibo Gai et al.   MOLECULAR PHARMACOLOGY

Liver X receptors in lipid signalling and membrane homeostasis

(2018) Bo Wang et al.   Nature Reviews Endocrinology

Noninvasive biomarkers in NAFLD and NASH — current progress and future promise

(2018) Vincent Wai-Sun Wong et al.   Nature Reviews Gastroenterology & Hepatology

Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand

(2018) Adriana Carino et al.   PHARMACOLOGICAL RESEARCH

Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages

(2018) Evan D. Muse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Liver X receptors regulate hepatic F4/80+CD11b+ Kupffer cells/macrophages and innate immune responses in mice

(2018) Kaori Endo-Umeda et al.   Scientific Reports

Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease

(2018) Mohammad Zarei et al.   Molecular Metabolism

LXR Suppresses Inflammatory Gene Expression and Neutrophil Migration through cis-Repression and Cholesterol Efflux

(2018) David G. Thomas et al.   Cell Reports

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

(2017) Jan Freark de Boer et al.   GASTROENTEROLOGY

Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration

(2017) Gloria Alvarez-Sola et al.   GUT

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Therapies in non-alcoholic steatohepatitis (NASH)

(2017) Abdul M. Oseini et al.   LIVER INTERNATIONAL

Targeting nuclear receptors for the treatment of fatty liver disease

(2017) Naoki Tanaka et al.   PHARMACOLOGY & THERAPEUTICS

Liver X receptor activation promotes differentiation of regulatory T cells

(2017) Martin Herold et al.   PLoS One

Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide

(2017) Mikhaïl Van Herck et al.   Nutrients

Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer–related Mortality

(2017) Arjun Gupta et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis

(2016) Nadira Ruzehaji et al.   ANNALS OF THE RHEUMATIC DISEASES

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

(2016) Alexandra Montagner et al.   GUT

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

(2015) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

(2015) Sven Francque et al.   JOURNAL OF HEPATOLOGY

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

(2015) Sungsoon Fang et al.   NATURE MEDICINE

Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease

(2015) Bratati Kahali et al.   SEMINARS IN LIVER DISEASE

LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling

(2015) Ayaka Ito et al.   eLife

Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis

(2014) Weibin Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Nuclear Receptors, RXR, and the Big Bang

(2014) Ronald M. Evans et al.   CELL

Expression of Liver X Receptor Correlates with Intrahepatic Inflammation and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

(2014) Sang Bong Ahn et al.   DIGESTIVE DISEASES AND SCIENCES

A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: A meta-analysis

(2014) Shamsul Mohd Zain et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

PPAR-alpha dependent regulation of vanin-1 mediates hepatic lipid metabolism

(2014) Janna A. van Diepen et al.   JOURNAL OF HEPATOLOGY

Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate

(2014) Yang Gao et al.   JOURNAL OF LIPID RESEARCH

The Medicinal Chemistry of Liver X Receptor (LXR) Modulators

(2014) Colin M. Tice et al.   JOURNAL OF MEDICINAL CHEMISTRY

Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells

(2014) Lei Hao et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

(2014) Julia Kozlitina et al.   NATURE GENETICS

Liver X receptors in lipid metabolism: opportunities for drug discovery

(2014) Cynthia Hong et al.   NATURE REVIEWS DRUG DISCOVERY

Gut microbiome and nonalcoholic fatty liver diseases

(2014) Lixin Zhu et al.   PEDIATRIC RESEARCH

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

(2013) Jean-Charles Fruchart   Cardiovascular Diabetology

The Hepatic Orosomucoid/α1-Acid Glycoprotein Gene Cluster Is Regulated by the Nuclear Bile Acid Receptor FXR

(2013) Geoffrey Porez et al.   ENDOCRINOLOGY

PPARalpha regulates the production of serum Vanin-1 by liver

(2013) Samuel Rommelaere et al.   FEBS LETTERS

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia

(2013) Pooja Jha et al.   HEPATOLOGY

Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells

(2013) Eva Morán-Salvador et al.   JOURNAL OF HEPATOLOGY

SCD1 activity in muscle increases triglyceride PUFA content, exercise capacity, and PPARδ expression in mice

(2013) Michael P. Rogowski et al.   JOURNAL OF LIPID RESEARCH

A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use

(2013) Sihao Liu et al.   NATURE

Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance

(2013) Yongjie Ma et al.   PHARMACEUTICAL RESEARCH

FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents

(2013) Barbara Renga et al.   PHARMACOLOGICAL RESEARCH

Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses

(2012) Nathanael J. Spann et al.   CELL

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

(2012) Luciano Adorini et al.   DRUG DISCOVERY TODAY

The Cholesterol Derivative 27-Hydroxycholesterol Reduces Steatohepatitis in Mice

(2012) Veerle Bieghs et al.   GASTROENTEROLOGY

Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace

(2012) György Baffy et al.   JOURNAL OF HEPATOLOGY

Protection from liver fibrosis by a peroxisome proliferator-activated receptor   agonist

(2012) K. Iwaisako et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PPARs at the crossroads of lipid signaling and inflammation

(2012) Walter Wahli et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Genetically modified mouse models for the study of nonalcoholic fatty liver disease

(2012) Perumal Nagarajan   WORLD JOURNAL OF GASTROENTEROLOGY

GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation

(2012) Radina Kostadinova et al.   Cell and Bioscience

Peroxisome Proliferator–Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice

(2011) Fanny Lalloyer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia

(2011) Yun-Jung Choi et al.   ATHEROSCLEROSIS

Very low density lipoprotein receptor promotes adipocyte differentiation and mediates the proadipogenic effect of peroxisome proliferator-activated receptor gamma agonists

(2011) Huan Tao et al.   BIOCHEMICAL PHARMACOLOGY

Activation of Liver X Receptors Attenuates Endotoxin-Induced Liver Injury in Mice with Nonalcoholic Fatty Liver Disease

(2011) Yuan Liu et al.   DIGESTIVE DISEASES AND SCIENCES

Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts

(2011) Eva Morán-Salvador et al.   FASEB JOURNAL

Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα)

(2011) Ana Fernández-Alvarez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

(2011) Harold E. Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction

(2011) Paulina Pettinelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The global obesity pandemic: shaped by global drivers and local environments

(2011) Boyd A Swinburn et al.   LANCET

Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE −/− Mice With Chronic Kidney Disease

(2010) Shinobu Miyazaki-Anzai et al.   CIRCULATION RESEARCH

Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice

(2010) Kristiaan Wouters et al.   FEBS LETTERS

Liver X Receptor Signaling Is a Determinant of Stellate Cell Activation and Susceptibility to Fibrotic Liver Disease

(2010) Simon W. Beaven et al.   GASTROENTEROLOGY

GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXR  in the hepatic acute phase response

(2010) N. Venteclef et al.   GENES & DEVELOPMENT

Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease

(2010) Weiqin Chen et al.   HEPATOLOGY

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

(2010) Giovanni Musso et al.   HEPATOLOGY

I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease

(2010) Luca Valenti et al.   HEPATOLOGY

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro

(2010) Jun Yu et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation

(2010) Sihao Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Animal models of nonalcoholic fatty liver disease

(2010) Lionel Hebbard et al.   Nature Reviews Gastroenterology & Hepatology

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of PPARβ/δ Causes a Psoriasis-Like Skin Disease In Vivo

(2010) Malgorzata Romanowska et al.   PLoS One

A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia

(2009) Mark J. Evans et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis

(2009) Michael Kremer et al.   HEPATOLOGY

Kupffer cells in non-alcoholic fatty liver disease: The emerging view

(2009) György Baffy   JOURNAL OF HEPATOLOGY

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

(2009) Songwen Zhang et al.   JOURNAL OF HEPATOLOGY

The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis

(2009) A. Mencarelli et al.   JOURNAL OF IMMUNOLOGY

Hepatic triacylglycerol hydrolysis regulates peroxisome proliferator-activated receptor α activity

(2009) Jessica M. Sapiro et al.   JOURNAL OF LIPID RESEARCH

L-FABP directly interacts with PPARα in cultured primary hepatocytes

(2009) Heather A. Hostetler et al.   JOURNAL OF LIPID RESEARCH

A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity

(2009) Silvia Sookoian et al.   JOURNAL OF LIPID RESEARCH

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses

(2009) Eduardo J Villablanca et al.   NATURE MEDICINE

Antiatherosclerotic effect of farnesoid X receptor

(2008) Andrea Mencarelli et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice

(2008) Elizabeth E. Girroir et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism

(2008) Matthew T Flowers et al.   CURRENT OPINION IN LIPIDOLOGY

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

(2008) C. Fernández-Miranda et al.   DIGESTIVE AND LIVER DISEASE

Systemic and Distal Repercussions of Liver-Specific Peroxisome Proliferator-Activated Receptor-α Control of the Acute-Phase Response

(2008) Roxane M. Mansouri et al.   ENDOCRINOLOGY

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Peroxisome proliferator-activated receptor-δ induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice

(2008) Xiaomei Qin et al.   HEPATOLOGY

Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet

(2008) B. Kong et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice

(2008) Yue-Min Nan et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Ligand Activation of Peroxisome Proliferator–Activated Receptor β/δ (PPARβ/δ) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression

(2008) Weiwei Shan et al.   TOXICOLOGICAL SCIENCES

PPARδ Enhances Keratinocyte Proliferation in Psoriasis and Induces Heparin-Binding EGF-Like Growth Factor

(2007) Malgorzata Romanowska et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY